Navigation Links
Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
Date:2/4/2009

n Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

     Media Contact:
     Dan Eramian
     T: 206.272.4343
     C: 206.854.1200
     E: media@ctiseattle.com
    http://www.CellTherapeutics.com/press_room

     Investors Contact:
     Ed Bell
     T: 206.272.4345
     Lindsey Jesch Logan
     T : 206.272.4347
     F : 206.272.4434
     E: invest@ctiseattle.com
    http://www.CellTherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
2. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
3. Omnitura Therapeutics Announces Private Placement Financing
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
6. CV Therapeutics Statement on Unsolicited Proposal From Astellas
7. Cell Therapeutics Receives Additional NASDAQ Notification
8. Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
9. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
10. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
(Date:5/16/2013)... 2013 The Stirling Ultracold Model ... Inc., Athens, OH, USA, won the Outstanding New Product ... Society for Biological and Environmental Repositories (ISBER) at their ... one product annually, recognizes the company’s development and introduction ... The award was presented to Global Cooling’s CEO ...
(Date:5/16/2013)... 2013 A new selection of ... Cole-Parmer is designed to meet the dynamic needs ... The new Cole-Parmer® MS-3400 Centrifuges are ... lab. They ensure a powerful and complete separation ... Their standard four-place swinging buckets hold 50-mL tubes. ...
(Date:5/16/2013)... , May 16, 2013  The registration deadline has ... Financial Officers (ABFO) 2013 National Conference, the premier conference ... May 28-31 at the Hilton San Diego Bayfront. ... this year,s conference and want to make sure as ... said Brandi Roberts , Chief Financial ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... , SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ... 2009. Revenue for the third quarter of 2009 was $25,000 ... Revenue for the nine months ended September 30, 2009 was ... 30, 2008. , Dendreon,s total operating expenses for the ...
... MADRID, November 11 Cellerix, a ... today announced the successful first closing of its financing ... current,shareholders and a select group of new investors. Cellerix ... , This round was led ...
... AMSTERDAM, November 11 Amsterdam ... human gene therapy,announced today that it has successfully treated ... proprietary gene therapy. The proof of,concept studies were performed ... of Rome, La Sapienza, Italy) and demonstrated,effectiveness in the ...
Cached Biology Technology:Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6Cellerix Raises EUR27 Million in a First Closing 2AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Jersey, and City University of New York have invented ... effectively clears organisms to be viewed under microscopes. Visikol ... is one of the few high-quality clearing solutions currently ... Enforcement Administration (DEA) due to its use as a ... for viewing organisms under a microscope. Without them, microscope ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... calculated that the bite force of the great white,s ... (also known as Big Tooth) is the highest ... carnivore ever to have existed. Shark researchers from ... Department of Primary Industries Fisheries (Australia) and University of ...
... Fruit and Vegetable Consumption Is Low among Black Men ... fruits and vegetables, daily consumption of these foods among ... researchers at Columbia and Temple universities, the University of ... study of 490 American and foreign-born black men between ...
... - JDRF said today that it has recognized the work ... the pace of science in understanding the autoimmune attack that ... severe complications of this chronic and life-threatening disease. ... Dr. Jeffrey A. Bluestone, Director of the Diabetes Center at ...
Cached Biology News:Great white's mighty bite revealed 2Highlights from the August 2008 Journal of the American Dietetic Association 2JDRF announces 2008 Scholar Award recipients 2JDRF announces 2008 Scholar Award recipients 3
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
Biology Products: